In a report issued on March 19, Brian Abrahams from RBC Capital maintained a Buy rating on Hookipa Pharma (HOOK), with a price target of $23.00. The company’s shares closed last Friday at $14.70, close to its 52-week high of $15.52.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 8.2% and a 48.3% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
Currently, the analyst consensus on Hookipa Pharma is a Strong Buy with an average price target of $22.33, a 66.6% upside from current levels. In a report issued on March 19, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.52 and a one-year low of $7.07. Currently, Hookipa Pharma has an average volume of 168.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body’s immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
